Most of the patients they see with suspected or confirmed IPF |
|
|
|
|
|
|
Difficult-to-treat patients |
|
|
|
|
|
|
When challenges related to the use of antifibrotic agents (such as side effect management; dose adjustments; adherence) arise |
|
|
|
|
|
|
When patients are declining/doing poorly |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|